NEW YORK (GenomeWeb News) – Veracyte and Genyzme today announced that the New York State Department of Health has cleared the way for Veracyte's molecular diagnostic test for inconclusive thyroid nodule results to be offered to patients in the state.

Memorial Sloan-Kettering Cancer Center will become one of the first institutions in the state to offer the test, which helps resolve inconclusive thyroid nodule results following traditional evaluation of fine needle aspiration (FNA) samples, the companies added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.